NEOPHARM, Inc. (NEOL) Tops Q2 EPS by 6c
More News related to NEOL
- NeoPharm Presents the Phase I Data for Patients with Metastatic Solid Tumors
- NeoPharm Names Dr. Aquilur Rahman as President and CEO
- NeoPharm Submits Application for a Multicenter, Open-Label, Phase II Study of LE-DT for Locally Advanced or Metastatic Pancreatic Cancer Patients as a Frontline Treatment
- NeoPharm (NEOL) Posts Q3 Loss of $0.06
- NeoPharm, Inc. Announces Third Quarter 2009 Financial Results and Clinical Trials Update
More News related to Earnings
- Cephalon (CEPH) Files Patent Infringement Lawsuit Against Teva (TEVA)
- Needham Lifts Price Target on Dyax (DYAX) to $8
- Novo Nordisk (NVO) Atophic Vaginitis Treatment Approved by U.S. FDA
- AEterna (AEZS) Announces FDA Fast Track Status for KRX-0401
- Keryx (KERX) Granted FDA Fast Track Designation for KRX-0401
NEOPHARM, Inc. (NASDAQ: NEOL) reports a Q2 loss of $0.13, 6 cents better than estimates.
Related Categories
EarningsStocks Mentioned
+0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
